ArticleAllergy2012
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
Article in Allergy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.Experimental hematology · 2014Trial
- Establishment and characterisation of a novel canine mast cell tumour cell line (C18).BMC veterinary research · 2025Article
- Analytical validation of a flow cytometric method for the detection and quantification of canine mast cells in peripheral blood, bone marrow, and lymph node.Frontiers in veterinary science · 2025Article
- Mutational Landscape ofVeterinary sciences · 2024Article
- Development of a flow cytometric panel to assess prognostic biomarkers in fine needle aspirates of canine cutaneous or subcutaneous mast cell tumors.Frontiers in veterinary science · 2023Article
- Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform-Physicochemical Properties and In Vitro Studies on Mastocytoma Cells.International journal of molecular sciences · 2022Article
- In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells.Veterinary medicine and science · 2021Article
- Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.Frontiers in veterinary science · 2021Review
- Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications.Molecules (Basel, Switzerland) · 2020Article
- Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.Veterinary and comparative oncology · 2019Article
- Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.Veterinary and comparative oncology · 2019Review
- Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.Journal of hematology & oncology · 2018Review
- Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.Leukemia · 2018Article
- The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.Veterinary and comparative oncology · 2018Article
- IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.Veterinary and comparative oncology · 2017Article
- Pharmacological targeting of allergen-specific T lymphocytes.Immunology letters · 2017Review
Corrections and comments
- Erratum issuedCorrigendum.2018
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced mast cell (MC) disorders are characterized by uncontrolled growth of neoplastic MC in various organs, mediator-related symptoms, and a poor prognosis. Kit mutations supposedly contribute to abnormal growth and drug resistance in these patients.
methodsWe established a novel canine mastocytoma cell line, NI-1, from a patient suffering from MC leukemia.
resultsNI-1 cells were found to form mastocytoma lesions in NOD/SCID IL-2Rgamma(null) mice and to harbor several homozygous Kit mutations, including missense mutations at nucleotides 107(C→T) and 1187(A→G), a 12-bp duplication (nucleotide 1263), and a 12-bp deletion (nucleotide 1550). NI-1 cells expressed several MC differentiation antigens, including tryptase, Kit, and a functional IgE receptor. Compared to the C2 mastocytoma cell line harboring a Kit exon 11 mutation, NI-1 cells were found to be less responsive against the Kit tyrosine kinase inhibitors (TKI) masitinib and imatinib, but were even more sensitive against proliferation-inhibitory effects of the mammalian target of rapamycin (mTOR) blocker RAD001 and PI3-kinase/mTOR blocker NVP-BEZ235. The Kit-targeting multikinase inhibitors PKC412 and dasatinib were also found to override TKI resistance in NI-1 cells, and produced growth inhibition with reasonable IC(50) values (<0.1 μM).
conclusionNI-1 may serve as a useful tool to investigate IgE-dependent reactions and mechanisms of abnormal growth and drug resistance in neoplastic MC in advanced mastocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.